EMERYVILLE, Calif., Feb. 8, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, will present at the 13th Annual BIO CEO & Investor Conference being held at the Waldorf Hotel in New York City. Dr. Ron Najafi, NovaBay’s Chief Executive Officer, will address attendees on Tuesday, February 15, 2011 at 8:00 AM Eastern Time (5:00 AM Pacific Time).
